1. Home
  2. GOVX vs CING Comparison

GOVX vs CING Comparison

Compare GOVX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GOVX
  • CING
  • Stock Information
  • Founded
  • GOVX 2001
  • CING 2012
  • Country
  • GOVX United States
  • CING United States
  • Employees
  • GOVX N/A
  • CING N/A
  • Industry
  • GOVX Biotechnology: Pharmaceutical Preparations
  • CING Biotechnology: Pharmaceutical Preparations
  • Sector
  • GOVX Health Care
  • CING Health Care
  • Exchange
  • GOVX Nasdaq
  • CING Nasdaq
  • Market Cap
  • GOVX N/A
  • CING 16.2M
  • IPO Year
  • GOVX N/A
  • CING 2021
  • Fundamental
  • Price
  • GOVX $0.97
  • CING $4.09
  • Analyst Decision
  • GOVX Strong Buy
  • CING Strong Buy
  • Analyst Count
  • GOVX 5
  • CING 4
  • Target Price
  • GOVX $12.40
  • CING $30.67
  • AVG Volume (30 Days)
  • GOVX 460.4K
  • CING 94.8K
  • Earning Date
  • GOVX 05-01-2025
  • CING 05-16-2025
  • Dividend Yield
  • GOVX N/A
  • CING N/A
  • EPS Growth
  • GOVX N/A
  • CING N/A
  • EPS
  • GOVX N/A
  • CING N/A
  • Revenue
  • GOVX $5,591,576.00
  • CING N/A
  • Revenue This Year
  • GOVX N/A
  • CING N/A
  • Revenue Next Year
  • GOVX N/A
  • CING N/A
  • P/E Ratio
  • GOVX N/A
  • CING N/A
  • Revenue Growth
  • GOVX N/A
  • CING N/A
  • 52 Week Low
  • GOVX $0.73
  • CING $1.80
  • 52 Week High
  • GOVX $11.18
  • CING $20.83
  • Technical
  • Relative Strength Index (RSI)
  • GOVX 45.22
  • CING 49.09
  • Support Level
  • GOVX $0.90
  • CING $3.90
  • Resistance Level
  • GOVX $1.15
  • CING $4.41
  • Average True Range (ATR)
  • GOVX 0.10
  • CING 0.25
  • MACD
  • GOVX 0.02
  • CING -0.03
  • Stochastic Oscillator
  • GOVX 55.56
  • CING 30.65

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: